Agios Pharmaceuticals Inc (AGIO) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Agios Pharmaceuticals Inc (NASDAQ:AGIO) have been given a consensus rating of “Buy” by the sixteen ratings firms that are presently covering the firm, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $93.67.

AGIO has been the subject of several recent research reports. ValuEngine raised Agios Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, May 2nd. UBS Group cut Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 14th. SunTrust Banks reissued a “buy” rating and set a $101.00 price objective (up from $80.00) on shares of Agios Pharmaceuticals in a report on Thursday, February 15th. Needham & Company LLC boosted their price objective on Agios Pharmaceuticals from $72.00 to $86.00 and gave the stock a “buy” rating in a report on Thursday, February 15th. Finally, Credit Suisse Group set a $95.00 price objective on Agios Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, April 11th.

In other news, insider Christopher Bowden sold 2,000 shares of the company’s stock in a transaction dated Thursday, April 12th. The stock was sold at an average price of $85.10, for a total value of $170,200.00. Following the completion of the sale, the insider now directly owns 2,881 shares of the company’s stock, valued at approximately $245,173.10. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Scott Biller sold 3,000 shares of the company’s stock in a transaction dated Tuesday, June 5th. The shares were sold at an average price of $93.37, for a total value of $280,110.00. Following the completion of the sale, the insider now directly owns 60,196 shares of the company’s stock, valued at $5,620,500.52. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 171,077 shares of company stock valued at $15,096,769. 3.02% of the stock is currently owned by company insiders.

Hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC increased its stake in shares of Agios Pharmaceuticals by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 369,512 shares of the biopharmaceutical company’s stock valued at $21,125,000 after acquiring an additional 4,073 shares during the last quarter. Xact Kapitalforvaltning AB bought a new stake in shares of Agios Pharmaceuticals in the 4th quarter valued at about $259,000. Virtus Fund Advisers LLC bought a new stake in shares of Agios Pharmaceuticals in the 4th quarter valued at about $379,000. HBK Investments L P bought a new stake in Agios Pharmaceuticals during the 4th quarter worth approximately $306,000. Finally, First Trust Advisors LP increased its stake in Agios Pharmaceuticals by 26.3% during the 4th quarter. First Trust Advisors LP now owns 813,647 shares of the biopharmaceutical company’s stock worth $46,516,000 after purchasing an additional 169,331 shares in the last quarter. 94.30% of the stock is owned by institutional investors.

NASDAQ AGIO traded up $1.89 on Thursday, hitting $94.19. 2,297 shares of the company were exchanged, compared to its average volume of 506,758. The company has a market cap of $5.35 billion, a price-to-earnings ratio of -14.03 and a beta of 2.00. Agios Pharmaceuticals has a 1-year low of $49.76 and a 1-year high of $97.59.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings results on Friday, May 4th. The biopharmaceutical company reported ($1.63) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.60) by ($0.03). The company had revenue of $8.80 million for the quarter, compared to analyst estimates of $11.93 million. Agios Pharmaceuticals had a negative return on equity of 61.70% and a negative net margin of 822.32%. The firm’s quarterly revenue was down 16.2% on a year-over-year basis. During the same quarter last year, the company earned ($1.56) EPS. research analysts predict that Agios Pharmaceuticals will post -6.51 earnings per share for the current year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit